Cemdisiran

N/A

Report date: 2026/03/27 20:01:50
NME

Base Information

Drug NameCemdisiran
Drug Alias NameL96 (ester ligand)ALN-CC5AD-62643ALN-62643L96
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionComplement C5 inhibitorsRNA interference
TargetsComplement C5
Therapy Area/IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic SyndromeGlomerulonephritis, IGA +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBosnia and HerzegovinaCanada +[40] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesZai Lab (Shanghai) Co LtdAlnylam Pharmaceuticals IncRegeneron Pharmaceuticals Inc
Inactive CompaniesMario Negri Institute For Pharmacological Research
Active IndicationsHemoglobinuria, ParoxysmalGeographic AtrophyMacular Degeneration +[6] 
Inactive IndicationsAtypical Hemolytic Uremic SyndromeGlomerulonephritis, IGA

Other Information

ATC CodeN/A
Related LinksN/A